Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT04512534Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Fudan University. Started Nov 2020; status: recruiting.
02
Drugs
sintilimabtucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04512534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512534.